# US 2020/0347106 A1 · Compositions and methods of using islet neogenesis peptides and analogs thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347106 A1
- Document ID: US20200347106A1
- Status: Published application
- Kind: A1
- Application number: 16/658,218
- Filed: 2019-10-21
- Published: 2020-11-05
- Earliest claimed: 2013-03-15
- Assignees: Shenzhen HighTide Biopharmaceutical, Ltd.
- Applicants: Shenzhen Hightide Biopharmaceutical, Ltd.
- Inventors: Liping LIU; Ru Bai
- Web page: https://patentgrep.com/patent/US20200347106A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/4705: {stimulating, promoting or activating activity}
- C07K 14/4733: {Acute pancreatitis-associated protein}
- C07K 14/4738: {Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR (cell cycle dependent kinases C12N9/12)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.

## Claims

### Claim at position 1

1-50. (canceled)

### Claim 51

A method for inhibiting inflammation, comprising administering to a subject in need thereof a peptide or analog thereof, wherein the peptide or analog thereof consists of a peptide or analog selected from the group consisting of SEQ ID NOS: 6, 8, 16-27, 32-40, 54-59, 61, 63-67 and 75-110.

### Claim 52 (depends on 51)

The method of claim 51, wherein the peptide or analog thereof consists of a peptide or analog selected from the group consisting of SEQ ID NOS: 6, 8, 18-27 and 56-59.

### Claim 53 (depends on 51)

The method of claim 51, wherein the peptide or analog thereof consists of a peptide or analog selected from the group consisting of SEQ ID NOS: 54, 55, 61 and 63-67.

### Claim 54 (depends on 51)

The method of claim 51, wherein the peptide or analog thereof consists of a peptide or analog selected from the group consisting of SEQ ID NOS: 16, 17, 32-40 and 75-110.
